Cyclacel Pharmaceuticals (NASDAQ:CYCC) Receives New Coverage from Analysts at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) in a report released on Wednesday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Cyclacel Pharmaceuticals Stock Up 2.3 %

Shares of CYCC opened at $1.79 on Wednesday. The business has a 50-day simple moving average of $2.33 and a two-hundred day simple moving average of $3.89. The stock has a market cap of $2.36 million, a price-to-earnings ratio of -0.07 and a beta of 0.54. Cyclacel Pharmaceuticals has a 52 week low of $1.52 and a 52 week high of $13.20.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last released its earnings results on Tuesday, March 19th. The biotechnology company reported ($6.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($6.35) by $0.12. The business had revenue of $0.03 million for the quarter. On average, equities analysts anticipate that Cyclacel Pharmaceuticals will post -18.7 earnings per share for the current fiscal year.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors.